- Home
- FTHY vs ANAB Comparison
FTHY vs ANAB Comparison
Compare FTHY & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHY
- ANAB
- Stock Information
- Founded
- FTHY 2020
- ANAB 2005
- Country
- FTHY United States
- ANAB United States
- Employees
- FTHY N/A
- ANAB N/A
- Industry
- FTHY Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- FTHY Finance
- ANAB Health Care
- Exchange
- FTHY Nasdaq
- ANAB Nasdaq
- Market Cap
- FTHY 535.0M
- ANAB 600.4M
- IPO Year
- FTHY N/A
- ANAB 2017
- Fundamental
- Price
- FTHY $14.68
- ANAB $21.17
- Analyst Decision
- FTHY
- ANAB Buy
- Analyst Count
- FTHY 0
- ANAB 11
- Target Price
- FTHY N/A
- ANAB $54.64
- AVG Volume (30 Days)
- FTHY 176.7K
- ANAB 636.7K
- Earning Date
- FTHY 01-01-0001
- ANAB 11-05-2024
- Dividend Yield
- FTHY 10.93%
- ANAB N/A
- EPS Growth
- FTHY N/A
- ANAB N/A
- EPS
- FTHY N/A
- ANAB N/A
- Revenue
- FTHY N/A
- ANAB $57,172,000.00
- Revenue This Year
- FTHY N/A
- ANAB $207.49
- Revenue Next Year
- FTHY N/A
- ANAB N/A
- P/E Ratio
- FTHY N/A
- ANAB N/A
- Revenue Growth
- FTHY N/A
- ANAB 282.17
- 52 Week Low
- FTHY $12.66
- ANAB $13.36
- 52 Week High
- FTHY $14.74
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- FTHY 49.32
- ANAB 37.43
- Support Level
- FTHY $14.61
- ANAB $18.03
- Resistance Level
- FTHY $14.91
- ANAB $22.94
- Average True Range (ATR)
- FTHY 0.14
- ANAB 1.39
- MACD
- FTHY 0.01
- ANAB 0.26
- Stochastic Oscillator
- FTHY 55.77
- ANAB 63.82
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).